MedTrace Logo

ARC101 in Advanced Solid Tumors

NCT06672185 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-04-03

No results posted yet for this study

Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

ARC101

ARC101 will be administered according to an assigned dose schedule.

Sponsors & Collaborators

  • Third Arc Bio

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-05
Primary Completion
2028-05-01
Completion
2028-08-01
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06672185 on ClinicalTrials.gov